Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Richard Eek"'
Autor:
Slavisa Ninkovic, Simon J Harrison, Je-Jung Lee, Nick Murphy, Jae Hoon Lee, Jane Estell, Vivien M Chen, Noemi Horvath, Kihuyn Kim, Richard Eek, Bradley Augustson, Soo-Mee Bang, Shang-Yi Huang, Rajeev Rajagopal, Ferenc Szabo, Daniel Engeler, Belinda E Butcher, Peter Mollee, Brian Durie, Wee Joo Chng, Hang Quach
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
This multicentre, phase II study of the Australian Lymphoma and Leukaemia Group (ALLG) and the Asian Myeloma Network (AMN) investigated fixed-duration (18-month) treatment with carfilzomib (K), thalidomide (T), and dexamethasone (d; KTd) in patients
Externí odkaz:
https://doaj.org/article/59301dc2a06d4af9a911c8be6500565d
Autor:
Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Stephen D. Smith, Jeanette K. Doorduijn, Carlos Panizo, Bijal D. Shah, Andrew J. Davies, Richard Eek, Eric Jacobsen, Arnon P. Kater, Tadeusz Robak, Preetesh Jain, Roser Calvo, Lin Tao, Michael Wang
Publikováno v:
Haematologica, Vol 109, Iss 1 (2023)
Externí odkaz:
https://doaj.org/article/c4917574fe414e708d9135d90b9b085d
Autor:
Melita Kenealy, Mark Hertzberg, Warwick Benson, Kerry Taylor, Ilona Cunningham, Will Stevenson, Devendra Hiwase, Richard Eek, Daniela Zantomio, Steve Jong, Meaghan Wall, Piers Blombery, Tracey Gerber, Marlyse Debrincat, Diana Zannino, John F. Seymour
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes. The ALLG MDS4 phase
Externí odkaz:
https://doaj.org/article/100c1073e6a747bdbc6ac870d32848d7
Autor:
Tomohide Tamura, Kazumasa Noda, Shinzoh Kudoh, José Baselga, Johan Vansteenkiste, Giuseppe Giaccone, Seiji Yano, Takeshi Horai, Kazuhiko Nakagawa, Ichiro Takata, Rui Ping Dong, Masahiro Fukuoka, Egbert F. Smit, Jean-Yves Douillard, Danny Rischin, Richard Eek, A. Feyereislova, Steven D. Averbuch, Yutaka Nishiwaki, Angela Macleod
Publikováno v:
Journal of Clinical Oncology. 41:1162-1171
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non–small-cell lung
Autor:
Sumayah Jamal, Adnan Nagrial, Matteo Carlino, Rasha Cosman, Anthony Joshua, Richard Eek, Sarina Piha-Paul, Omid Hamid, Jenny Liu
Publikováno v:
Cancer Research. 83:CT267-CT267
Programmed cell death 1 (PD-1) inhibitors have minimal effect in ovarian cancer (OC) and pancreatic ductal adenocarcinoma (PDAC). Selective endothelin B receptor (ETBR) blockade stimulates T cell tumor infiltration and synergizes with anti-PD-1 thera
Autor:
Justin Jackson, Chun Chan, Jacqueline McBurnie, Gina La Hera-Fuentes, John Burston, Leisa Bridges, Craig Underhill, Richard Eek, Linda Hueston, Matthew O'Sullivan, Dominic E. Dwyer
Publikováno v:
Australian and New Zealand Journal of Public Health. 47:100003
Autor:
William Reed, Richard Eek, Andrew Nicol, Radha Prathikanti, Rebecca Elstrom, Hannah Rose, Michael F. Leahy, Aileen Cohen, Jingjing Schneider, Xavier Badoux, Constantine S. Tam, Nicholas Wickham, H. Miles Prince, Sushrut Patil, Jane Huang, Hang Quach, Ian W. Flinn
Publikováno v:
Blood Adv
Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early effic
Autor:
Janice Lu, Kevin M Kalinsky, Debu Tripathy, George W Sledge, William Gradishar, Ruth O’Regan, Joyce O’Shaughnessy, Shanu Modi, Joshua Drago, Haeseong Park, Amelia McCartney, Sophia Frentzas, Catherine Shannon, Katharine Cuff, Richard Eek, Miguel Idzwan Martin, Giuseppe Curigliano, Guy Jerusalem, Chiun-Sheng Huang, Michael Press, Matt Li, Dong Xu, Cynthia Song, Richard Huhn, Jinchun Yan, Sara Hurvitz
Publikováno v:
Cancer Research. 82:OT1-02
Background: The HER2 receptor is a cancer driver which is overexpressed on 15-20% of breast cancers. Though historically survival is poor with this disease subtype, HER2+ targeted therapy has improved survival in both early and advanced disease. In s
Autor:
Mengjun Wang, Jehan Dupuis, T. Lamy, Andrew Davies, Carlos Panizo, Tadeusz Robak, Eric N. Jacobsen, Lucie Oberic, S. Le Gouill, Simon Rule, Richard Eek, Arnon P. Kater, Monika Długosz-Danecka, O. Casasnovas, Roser Calvo, J.K. Doorduijn, Preetesh Jain, F. Morschhauser, Stephen D. Smith, Lin Tao, Bhavana Shah, Ghandi Damaj, P. L. Zinzani, Andre Goy
Publikováno v:
Hematological Oncology. 39
Autor:
Warwick Benson, Tracey Gerber, Meaghan Wall, K. M. Taylor, Devendra K Hiwase, Piers Blombery, Richard Eek, Melita Kenealy, Diana Zannino, John F. Seymour, Marlyse A. Debrincat, Steve Jong, Mark P. Hertzberg, Daniela Zantomio, Will Stevenson, Ilona Cunningham
Publikováno v:
Haematologica
Standard treatment for higher risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast acute myeloid leukemia (AML) is azacitidine. In single arm studies, the addition of lenalidomide had been suggested to improve ou